LEIDEN, NETHERLANDS--(Marketwire - January 16, 2008) - Dutch biotechnology company Crucell N.V. today reacted to a press release issued by German company CEVEC Pharmaceuticals GmbH. In their press release of 14 January 2008, CEVEC announced that one of Crucell's PER.C6® patents for protein production was restricted by a recent decision of the European Patent Office. Crucell states that the suggestions made in CEVEC's press release are misleading.
